The onlinevideoseems to promise everything an arthritis patient could want.
The six-minute segment mimics a morning talk show, using a polished TV host to interview guests around a coffee table. Dr. Adam Pourcho extols the benefits of stem cells and regenerative medicine for healing joints without surgery. Pourcho, a sports medicine specialist, says he has used platelet injections to treat his own knee pain, as well as a tendon injury in his elbow. Extending his arm, he says, Its completely healed.
Brendan Hyland, a gym teacher and track coach, describes withstanding intense heel pain for 18 months before seeing Pourcho. Four months after the injections, he says, he was pain-free and has since gone on a 40-mile hike.
I dont have any pain that stops me from doing anything I want, Hyland says.
Critics suggest the hospitals are exploiting desperate patients and profiting from trendy but unproven treatments.
The videos cheerleading tone mimics theinfomercialsused to promote stem cell clinics, several of which have recently gotten into hot water with federal regulators, saidDr. Paul Knoepfler, a professor of cell biology and human anatomy at the University of California-Davis School of Medicine. But the marketing video wasnt filmed by a little-known operator.
It was sponsored bySwedishMedical Center, the largest nonprofit health provider in the Seattle area.
Swedish is one of a growing number ofrespected hospitalsandhealth systems including theMayo Clinic, theCleveland Clinicand theUniversity of Miami that have entered the lucrative business ofstem cellsandrelated therapies, including platelet injections. Typical treatments involveinjecting patients joints with their own fatorbone marrowcells, or with extracts ofplatelets, the cell fragments known for their role in clotting blood. Many patients seek out regenerative medicine to stave off surgery, even though theevidencesupporting these experimental therapies isthin at best, Knoepfler said.
Hospitals say theyre providing options to patients who have exhausted standard treatments. But critics suggest the hospitals are exploiting desperate patients and profiting from trendybut unproventreatments.
TheFood and Drug Administrationis attempting to shut down clinics that hawk unapproved stem cell therapies, which have been linked toseveral cases of blindnessand atleast 12 serious infections. Although doctors usually need preapproval to treat patients with human cells, the FDA has carved out ahandful of exceptions,as long as the cells meet certain criteria, said Barbara Binzak Blumenfeld, an attorney who specializes in food and drug law at Buchanan Ingersoll & Rooney in Washington.
Hospitals like Mayo are careful to follow these criteria, to avoid running afoul of the FDA, said Dr. Shane Shapiro, program director for the Regenerative Medicine Therapeutics Suites at Mayo Clinics campus in Florida.
While hospital-based stem cell treatments may be legal, theres nostrong evidencethey work, said Leigh Turner, an associate professor at the University of Minnesotas Center for Bioethics who has published a series of articles describing the size and dynamics of thestem cell market.
FDA approval isnt needed and physicians can claim they arent violating federal regulations, Turner said. But just because something is legal doesnt make it ethical.
For doctors and hospitals, stem cells are easy money, Turner said. Patients typically paymore than $700a treatment for platelets and up to$5,000for fat and bone marrow injections. As a bonus, doctors dont have to wrangle with insurance companies, which view the procedures asexperimentaland largelydont cover them.
For doctors and hospitals, stem cells are easy money.
Its an out-of-pocket, cash-on-the-barrel economy, Turner said. Across the country, clinicians at elite medical facilities are lining their pockets by providingexpensive placebos.
Some patient advocates worry that hospitals are more interested in capturing a slice of the stem-cell market than in proving their treatments actually work.
Its lucrative. Its easy to do. All these reputable institutions, they dont want to miss out on the business, said Dr. James Rickert, president of the Society for Patient Centered Orthopedics, which advocates for high-quality care. It preys on peoples desperation.
In a joint statement, Pourcho and Swedish defended the online video.
The terminology was kept simple and with analogies that the lay person would understand, according to the statement. As with any treatment that we provide, we encourage patients to research and consider all potential treatment options before deciding on what is best for them.
But Knoepfler said the guests on the video make several unbelievable claims.
At one point, Dr. Pourcho says thatplatelets release growth factorsthat tell the brain which types of stem cells to send to the site of an injury. According to Pourcho, these instructions make sure that tissues are repaired with the appropriate type of cell, and so you dont get, say, eyeball in your hand.
Knoepfler, who has studied stem cell biology for two decades, said he has never heard of any possibility of growing eyeball or other random tissues in your hand. Knoepfler, who wrote about the video in February on his blog,The Niche, said, Theres no way that the adult brain could send that kind of stem cells anywhere in the body.
The marketing video debuted in July on KING-TV, a Seattle station, as part of a local lifestyles show called New Day Northwest. Although much of the show is produced by the KING 5 news team, some segments like Pourchos interview are sponsored by local advertisers, said Jim Rose, president and general manager of KING 5 Media Group.
After being contacted by KHN, Rose asked Swedish to remove the video from YouTube because it wasnt labeled as sponsored content. Omitting that label could allow the video to be confused with news programming. The video now appears only on the KING-TV website, where Swedish is labeled as the sponsor.
The goal is to clearly inform viewers of paid content so they can distinguish editorial and news content from paid material, Rose said. We value the publics trust.
Federal authorities have recently begun cracking down on doctors who make unproven claims or sell unapproved stem cell products.
In October, theFederal Trade Commissionfined stem cell clinics millions of dollars for deceptive advertising, noting that the companies claimed to be able to treat or cure autism, Parkinsons disease and other serious diseases.
In a recent interview Scott Gottlieb, the FDA commissioner, said the agency will continue to go after what he called bad actors.
Withmore than 700stem cell clinics in operation, the FDA is first targeting those posing the biggest threat, such as doctors who inject stem cells directly into the eye or brain.
There are clearly bad actors who are well over the line and who are creating significant risks for patients, Gottlieb said.
Federal authorities have recently begun cracking down on doctors who make unproven claims or sell unapproved stem cell products.
Gottlieb, set to leave office April 5, said hes also concerned about the financial exploitation of patients in pain.
Theres economic harm here, where products are being promoted that arent providing any proven benefits and where patients are paying out-of-pocket, Gottlieb said.
Dr. Peter Marks, director of the FDAs Center for Biologics Evaluation and Research, said there is a broad spectrum of stem cell providers, ranging from university scientists leading rigorous clinical trials to doctors who promise stem cells are for just about anything. Hospitals operate somewhere in the middle, Marks said.
The good news is that theyre somewhat closer to the most rigorous academics, he said.
The Mayo Clinics regenerative medicine program, for example, focuses conditions such asarthritis, where injections pose few serious risks, even if thats not yet the standard of care, Shapiro said.
Rickert said its easy to see why hospitals are eager to get in the game.
The market for arthritis treatment is huge and growing. At least30 million Americanshave the most common form of arthritis, with diagnoses expected to soar as the population ages. Platelet injections for arthritis generatedmore than $93 millionin revenue in 2015, according to an article last year in The Journal of Knee Surgery.
We have patients in our offices demanding these treatments, Shapiro said. If they dont get them from us, they will get them somewhere else.
Doctors at the Mayo Clinic try to provide stem cell treatments and similar therapies responsibly, Shapiro said. Ina paper published this year,Shapiro described the hospitals consultation service, in which doctors explain patients options and clear up misconceptions about what stem cells and other injections can do. Doctors can refer patients to treatment or clinical trials.
Most of the patients do not get a regenerative [stem cell] procedure, Shapiro said. They dont get it because after we have a frank conversation, they decide, Maybe its not for me.
Although some hospitals boast of high success rates for their stem cell procedures,published researchoften paints a different story.
TheMayo Clinic websitesays that 40 to 70% of patients find some level of pain relief. Atlanta-basedEmory Healthcareclaims that 75 to 80% of patients have had significant pain relief and improved function. In the Swedish video, Pourcho claims we can treat really any tendon or any joint with PRP.
The strongest evidence for PRP is in pain relief for arthritic knees and tennis elbow, where it appears to be safe and perhaps helpful, said Dr. Nicolas Piuzzi, an orthopedic surgeon at the Cleveland Clinic.
But PRP hasnt been proven to help every part of the body, he said.
PRP has been linked to serious complications when injected to treatpatellar tendinitis,an injury to the tendon connecting the kneecap to the shinbone. In a 2013 paper, researchers described the cases of three patients whose pain got dramatically worse after PRP injections. One patient lost bone and underwent surgery to repair the damage.
People will say, If you inject PRP, you will return to sports faster, said Dr. Freddie Fu, chairman of orthopedic surgery at the University of Pittsburgh Medical Center. But that hasnt been proven.
A2017 studyof PRP found it relieved knee pain slightly better than injections of hyaluronic acid. But thats nothing to brag about, Rickert said, given thathyaluronic acid therapy doesnt work, either. While some PRP studies have shown morepositive results, Rickert notes that most were so small orpoorly designedthat theirresults arent reliable.
In its 2013 guidelines for knee arthritis, theAmerican Academy of Orthopaedic Surgeonssaid it is unable to recommend for or against PRP.
PRP is sort of a buyer beware situation, said Dr. William Li, president and CEO of the Angiogenesis Foundation, whose research focuses on blood vessel formation. Its the poor mans approach to biotechnology.
Tests of other stem cell injections also have failed to live up to expectations.
Shapiro published a rigorously designed study last year inCartilage, a medical journal, that found bone marrow injections were no better at relieving knee pain than saltwater injections. Rickert noted that patients who are in pain often get relief from placebos. The more invasive the procedure, the stronger the placebo effect, he said, perhaps because patients become invested in the idea that an intervention will really help. Even saltwater injections help 70% of patients, Fu said.
A 2016 review in theJournal of Bone and JointSurgery concluded that the value and effective use of cell therapy in orthopaedics remain unclear. The following year, a review in theBritish Journal of Sports Medicineconcluded, We do not recommend stem cell therapy for knee arthritis.
Shapiro said hospitals and health plans are right to be cautious.
Many patients have trouble sorting through the hype.
The insurance companies dont pay for fat grafting or bone-marrow aspiration, and rightly so, Shapiro said. Thats because we dont have enough evidence.
Rickert, an orthopedist in Bedford, Ind., said fat, bone marrow and platelet injections should be offered only through clinical trials, which carefully evaluate experimental treatments. Patients shouldnt be charged for these services until theyve been tested and shown to work.
Orthopedists surgeons who specialize in bones and muscles have a history of performing unproven procedures, includingspinal fusion, surgery forrotator cuff diseaseandarthroscopyfor worn-out knees, Turner said. Recently, studies have shown them to be no more effective than placebos.
Some argue that joint injections shouldnt be marketed as stem cell treatments at all.
Piuzzi said he prefers to call the injections orthobiologics,noting that platelets are not even cells, let alone stem cells. The number of stem cells in fat and bone marrow injections is extremely small, he said. In fat tissue, only about 1 in 2,000 cells is a stem cell, according to a March paper inThe Bone & Joint Journal. Stem cells are even rarer in bone marrow, where 1 in 10,000 to 20,000 cells is a stem cell.
Patients are attracted to regenerative medicine because they assume it will regrow their lost cartilage, Piuzzi said. Theres no solid evidence that the commercial injections used today spur tissue growth, Piuzzi said. Although doctors hope that platelets will release anti-inflammatory substances, which could theoretically help calm an inflamed joint, they dont know why some patients who receive platelet injections feel better, but others dont.
So, it comes as no surprise that many patients have trouble sorting through the hype.
Florida resident Kathy Walsh, 61, said she wasted nearly $10,000 on stem cell and platelet injections at a Miami clinic, hoping to avoid knee replacement surgery.
When Walsh heard about a doctor in Miami claiming to regenerate knee cartilage with stem cells, it seemed like an answer to a prayer, said Walsh, of Stuart, Fla. Youre so much in pain and so frustrated that you cling to every bit of hope you can get, even if it does cost you a lot of money.
The injections eased her pain for only a few months. Eventually, she had both knees replaced. She has been nearly pain-free ever since. My only regret, she said, is that I wasted so much time and money.
KaiserHealthNewsis an editorially independent program of the Henry J.KaiserFamily Foundation, a nonprofit, nonpartisanhealthpolicy research and communication organization not affiliated withKaiserPermanente. You can view the original report on itswebsite.
- Clinical Outcomes Using RYONCIL (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles... - May 26th, 2020
- Stem Cell Therapy Market 2020: Consumption, Trends, Growth, Types,Industrial Applications, Leading Companies & Forecast till 2026 - Jewish Life... - May 26th, 2020
- Silver Nanoparticle-Induced Apoptosis in ARPE-19 Cells Is Inhibited by | IJN - Dove Medical Press - May 26th, 2020
- Adipose Derived Stem Cell Therapy Market (Impact of COVID-19) Sales To 2026 Anticipeted By Key Players - Surfacing Magazine - May 26th, 2020
- Life celebrates 20th anniversary during English Tourism Week - North East Times - May 26th, 2020
- Stem Cell Therapy Market To Boom In Near Future By 2027 Scrutinized In New Research - News Distinct - May 26th, 2020
- Retinitis Pigmentosa Treatment Market : Growth factor with key drivers, industry research, regional forecast - Jewish Life News - May 26th, 2020
- COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026 - Jewish Life News - May 26th, 2020
- Global Myelofibrosis Treatment Market to Register Growth in Incremental Opportunity During the Forecast Period 2016 2022 - Cole of Duty - May 26th, 2020
- COVID-19 treatments are a better bet than a vaccine - Stockhead - May 26th, 2020
- Autologous Cell Therapy Market 2020 Competition by Manufacturers, Concentration Rate, Production Volume, Price|BioTime, Inc., BrainStorm Cell... - May 26th, 2020
- Mesoblast : 3 Articles on RYONCIL GvHD Trial Results Published in BBMT - Marketscreener.com - May 25th, 2020
- Will there still be massage treatments? What the future of luxury spas looks like - Telegraph.co.uk - May 25th, 2020
- The Week Ahead In Biotech: ASCO Presentations In The Spotlight - Benzinga - May 25th, 2020
- Lawyer celebrates 40 years with Blythe Liggins after first day hiccup - Leamington Observer - May 24th, 2020
- Stem Cell Banking Market Market Share, Size 2020| Emerging Rapidly with Global Latest Trends, Growth, Revenue, Demand and Forecast to 2027 - Cole of... - May 24th, 2020
- Covid-19 Impact on Cancer Stem Cell Therapy Market Trends Analysis, Top Manufacturers, Shares, Growth Opportunities, Statistics & Forecast to 2026... - May 24th, 2020
- What is a cytokine storm? And why is its prevention key to treating Covid-19? - Scroll.in - May 24th, 2020
- Covid-19 Impact On Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 : Industry Trends, Size, Growth, Swot Analysis By Top Key... - May 24th, 2020
- Restoring vision to the blind - Science Magazine - May 24th, 2020
- Ontario Announces First Phase of Research Projects to Fight COVID-19 - Government of Ontario News - May 24th, 2020
- Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19 - Pulmonology Advisor - May 23rd, 2020
- World coronavirus Dispatch: Animal Stem Cell Therapy Market Size, Share, Statistics, Demand and Revenue; Forecast To 2025 - 3rd Watch News - May 23rd, 2020
- Cells for Cells and Austrianova announce publication on novel method to produce stem cell exosomes - BioSpace - May 23rd, 2020
- The Economic Impact of Coronavirus on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market : In-depth study on Industry Size and Analysis on... - May 23rd, 2020
- World coronavirus Dispatch: Rheumatoid Arthritis Stem Cell Therapy market to witness robust revenue growth between 2018 to 2028 - Cole of Duty - May 23rd, 2020
- Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 - TheStreet - May 23rd, 2020
- Animal Stem Cell Therapy Market: Overview, Opportunities, Analysis of Features, Benefits, Manufacturing Cost and Forecast To 2025 - Cole of Duty - May 23rd, 2020
- Looking toward the Future of Cell & Gene Therapies - Genetic Engineering & Biotechnology News - May 22nd, 2020
- NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients - Yahoo... - May 22nd, 2020
- Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and... - May 22nd, 2020
- Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 - The Conversation US - May 22nd, 2020
- Analysis on Impact of COVID-19-Stem Cell Therapy Market 2020-2024 | Increase in Awareness of Stem Cell Therapy to Boost Growth | Technavio - Business... - May 19th, 2020
- NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients - Business... - May 19th, 2020
- Stem Cell Therapy Improved Quality of Life in Patients with Microvascular Dysfunction - Diagnostic and Interventional Cardiology - May 19th, 2020
- Can stem cell therapy help - Greater Kashmir - May 19th, 2020
- Family needs to raise 40k towards potentially life-changing treatment for mum with MS - Coventry Telegraph - May 19th, 2020
- Interim Results of Phase I Study Confirms Safety with Early Signs of Efficacy for TRPH-222 in NHL - OncoZine - May 19th, 2020
- Stem Cell Treatments Market Report, History and Forecast 2015-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application - Express... - May 19th, 2020
- Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19 - Monthly Prescribing Reference - May 17th, 2020
- Coronavirus: Emirati dentist who received stem cell therapy doing well - Gulf News - May 17th, 2020
- Stem Cell Therapy Market Research Report 2020 By Size, Share, Trends, Analysis and Forecast to 2026 - Cole of Duty - May 17th, 2020
- Outcomes of Hematopoietic Stem Cell Transplantation in Children With Diamond-Blackfan Anemia - Hematology Advisor - May 17th, 2020
- Venetoclax May Play Role as Salvage Therapy in Multiply Relapsed MCL - Targeted Oncology - May 17th, 2020
- The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows - Benzinga - May 17th, 2020
- GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming American Association for Cancer Research (AACR)... - May 17th, 2020
- Michael Hiltzik: Don't be taken in by stem cell firms offering unsubstantiated therapies for COVID-19 - Rome News-Tribune - May 15th, 2020
- Mike Tyson lifts lid on training regime and stem-cell therapy ahead of comeback - Metro.co.uk - May 15th, 2020
- Global Stem Cell Partnering Terms and Agreements 2010-2020 - ResearchAndMarkets.com - Business Wire - May 15th, 2020
- Mum's brutal stem cell treatment has 'all been worth it' as she enjoys time with family - Grimsby Live - May 15th, 2020
- Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment... - May 15th, 2020
- Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock - Motley Fool - May 15th, 2020
- Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Re | CEOR - Dove Medical Press - May 15th, 2020
- Mesoblast raises $138m from investors on hopes for COVID-19 treatment - Sydney Morning Herald - May 15th, 2020
- Group of Genes Have Altered Expression in Autism - Technology Networks - May 15th, 2020
- SENECA BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - May 15th, 2020
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 15th, 2020
- Cardio Stem Cell Therapy Used to Treat Critically Ill Covid-19 Patients - Physician's Weekly - May 14th, 2020
- Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131 - GlobeNewswire - May 14th, 2020
- Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a... - May 14th, 2020
- Scientists generate millions of nave human pluripotent stem cells, far more than have ever been produced - UB News Center - May 14th, 2020
- bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual... - May 14th, 2020
- Regenerative Medicine Industry Outlook to 2025 Featuring Novartis, Vericel, Integra Lifesciences, Mimedx Group, Stryker, Wright Medical, Roche and... - May 14th, 2020
- Doctors just discovered another promising coronavirus therapy - BGR - May 14th, 2020
- Cell therapy firm boosts odds for blood cancer patients as key trial succeeds - The Times of Israel - May 14th, 2020
- Tiziana Life Sciences Announces Data Demonstrating StemPrintER's Superiority Compared to Oncotype DX in Providing Prognostic Information to... - May 14th, 2020
- Global Animal Stem Cell Therapy Market Types, Application, and Regions, Forecast 2020- 2025. :Global Globalmarketers.biz - Cole of Duty - May 14th, 2020
- FTC Letters Warn Marketers to Stop Making Unsupported Claims That Their Products and Therapies Can Effectively Prevent or Treat COVID-19 - New... - May 10th, 2020
- Autolus Therapeutics Plc (AUTL) Q1 2020 Earnings Call Transcript - The Motley Fool - May 10th, 2020
- Combating coronavirus: UAE announces its highest ever recoveries in a day - Khaleej Times - May 10th, 2020
- Orchard Therapeutics (ORTX) Q1 2020 Earnings Call Transcript - Motley Fool - May 10th, 2020
- Stem Cell Therapy Market To Boom In Near Future By 2027 Scrutinized In New Research - Cole of Duty - May 9th, 2020
- FDA approves Tabrecta, first targeted therapy to treat metastatic NSCLC - The Cancer Letter - May 9th, 2020
- FTC warns Oregon companies to stop claiming they can prevent or treat COVID-19 - KGW.com - May 9th, 2020
- Region 1: Chemotherapy, Part II - MedPage Today - May 9th, 2020
- World Thalassemia Day 2020: Causes, Symptoms, Diagnosis And Treatment of The Disease - India.com - May 9th, 2020
- Avrobio taps Magenta's ADC in ongoing quest to improve gene therapy conditioning - FierceBiotech - May 9th, 2020
- COVID-19: Responding to the business impacts of Rise in expanse of applications boosts Rheumatoid Arthritis Stem Cell Therapy market 2018 to 2028 3w... - May 9th, 2020
- Cell Therapy Market 2020 by Various Types, End-Use Application, Major Players, Forecast 2025 - Cole of Duty - May 9th, 2020
- Global Stem Cell Therapy Market 2020 With COVID-19 Update by Development factors analysis, Competitive Strategies and Forecast to 2025 - Bandera... - May 9th, 2020